The current state of targeted agents in rectal cancer.

about

Synthesis and cytotoxicity studies of 1-propenyl-1,3-dihydro-benzimidazol-2-one.Proactive strategies for regorafenib in metastatic colorectal cancer: implications for optimal patient management.

P2860

Q35752585-460C0652-5244-45B2-B0CF-5A518E3517DE Q37630186-92D92AF4-2DB8-48A7-A607-8FB9231B7516

P2860

The current state of targeted agents in rectal cancer.

Item

http://www.wikidata.org/entity/Q35996651

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

The current state of targeted agents in rectal cancer.

@ast

The current state of targeted agents in rectal cancer.

@en

type

Item

label

The current state of targeted agents in rectal cancer.

@ast

The current state of targeted agents in rectal cancer.

@en

prefLabel

The current state of targeted agents in rectal cancer.

@ast

The current state of targeted agents in rectal cancer.

@en

P1476

The current state of targeted agents in rectal cancer.

@en

P2093

Cathy Eng

http://www.w3.org/2001/XMLSchema#string

Dae Dong Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer.

Cetuximab for the treatment of colorectal cancer.

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer.

Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer

Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer

Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer

Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer

Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

P304

406830

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/406830

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-05-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225276755

http://www.w3.org/2001/XMLSchema#string

P698

22675625

http://www.w3.org/2001/XMLSchema#string

P932

3362864

http://www.w3.org/2001/XMLSchema#string

The current state of targeted agents in rectal cancer.

about

P2860

P2860

The current state of targeted agents in rectal cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P5875

P698

P932